Juno Therapeutics Gmbh

Editas Medicine, Inc.

Stephen Michael Burleigh

Christopher Heath Nye

Stephen Jacob Goldfless

Cameron Brandt

Brian J Belmont

Blythe D Sather

Yue Jiang

Alexandra Croft

David Jeffrey Huss

Timothy G Johnstone

James Sissons

Haley Peper

Dean Y Toy

Gordon Grant Welstead

David Koppstein

Hieu Nguyen

Sonia Timberlake

Queenie Vong

Christopher Borges

Provided herein are engineered immune cells, e.g. T cells, expressing a chimeric receptor comprising an intracellular region comprising a CD3zeta (CD3ζ) signaling domain. In some embodiments, the engineered immune cells contain a modified CD247 locus that encodes the chimeric receptor or a portion thereof. In some embodiments, at least a portion of a CD3zeta chain encoded by CD247 genomic locus. Also provided are cell compositions containing the engineered immune cells, nucleic acids for engineering cells, and methods, kits and articles of manufacture for producing the engineered cells, such as by targeting a transgene encoding a portion of a chimeric receptor for integration into a region of a CD247 genomic locus. In some embodiments, the engineered cells, e.g. T cells, can be used in connection with cell therapy, including in connection with cancer immunotherapy comprising adoptive transfer of the engineered cells.

Cells expressing a chimeric receptor from a modified CD247 locus, related polynucleotides and methods

Provided are binding molecules, such as TCRs or antigen binding fragments thereof and antibodies and antigen-binding fragments thereof, such as those that recognize or bind human papilloma virus (HPV) 16, including HPV 16 E6 and HPV 16 E7. Also provided are engineered cells containing such binding molecules, compositions containing the binding molecules or engineered cells, and methods of treatment, such as administration of the binding molecules, engineered cells, or compositions.

HPV-specific binding molecules

Growing community of inventors

Seattle, WA, United States of America

Stephen Michael Burleigh